244 related articles for article (PubMed ID: 10827375)
1. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Cohen M; Stinnett SS; Weatherley BD; Gurfinkel EP; Fromell GJ; Goodman SG; Fox KA; Califf RM
Am Heart J; 2000 Jun; 139(6):962-70. PubMed ID: 10827375
[TBL] [Abstract][Full Text] [Related]
2. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
3. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
[TBL] [Abstract][Full Text] [Related]
4. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
5. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
[TBL] [Abstract][Full Text] [Related]
6. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Mahaffey KW; Yang Q; Pieper KS; Antman EM; White HD; Goodman SG; Cohen M; Kleiman NS; Langer A; Aylward PE; Col JJ; Reist C; Ferguson JJ; Califf RM;
J Gen Intern Med; 2008 Mar; 23(3):310-6. PubMed ID: 18196350
[TBL] [Abstract][Full Text] [Related]
7. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
8. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes.
Savonitto S; Cohen MG; Politi A; Hudson MP; Kong DF; Huang Y; Pieper KS; Mauri F; Wagner GS; Califf RM; Topol EJ; Granger CB
Eur Heart J; 2005 Oct; 26(20):2106-13. PubMed ID: 15987706
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
[TBL] [Abstract][Full Text] [Related]
12. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Demers C
Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database study.
Stone PH; Thompson B; Zaret BL; Chaitman B; Gibson RS; Schweiger MJ; Steingart R; Kirshenbaum J; Thompson C; Fung A; McCabe CH; Knatterud GL; Braunwald E
Eur Heart J; 1999 Aug; 20(15):1084-93. PubMed ID: 10413638
[TBL] [Abstract][Full Text] [Related]
15. ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification.
Yan AT; Yan RT; Tan M; Chow CM; Fitchett DH; Georgescu AA; Hassan Q; Luchansky J; Langer A; Goodman SG;
Am Heart J; 2006 Aug; 152(2):270-6. PubMed ID: 16875907
[TBL] [Abstract][Full Text] [Related]
16. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Simoons ML; Bobbink IW; Boland J; Gardien M; Klootwijk P; Lensing AW; Ruzyllo W; Umans VA; Vahanian A; Van De Werf F; Zeymer U;
J Am Coll Cardiol; 2004 Jun; 43(12):2183-90. PubMed ID: 15193678
[TBL] [Abstract][Full Text] [Related]
17. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Mehta RH; Greenbaum AB; Lokhnygina Y; Newby LK; Van De Werf F; Armstrong PW; Pieper KS; Califf RM; Granger CB; Harrington RA
J Interv Cardiol; 2007 Oct; 20(5):299-306. PubMed ID: 17880325
[TBL] [Abstract][Full Text] [Related]
18. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
19. Combined prognostic utility of ST segment in lead aVR and troponin T on admission in non-ST-segment elevation acute coronary syndromes.
Kosuge M; Kimura K; Ishikawa T; Ebina T; Hibi K; Tsukahara K; Kanna M; Iwahashi N; Okuda J; Nozawa N; Ozaki H; Yano H; Kusama I; Umemura S
Am J Cardiol; 2006 Feb; 97(3):334-9. PubMed ID: 16442391
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
